sahmcapital.com
EOM Pharmaceutical plans 15-20-patient Phase II Crohn's disease trial of EOM613 in Q1 2026
A new investigational drug (EOM613) is entering a small Phase II trial for Crohn’s disease, which could become a future treatment option if later studies are positive. Early-stage industry updates can indicate where research and trial opportunities may appear.
Patients with Crohn’s disease interested in clinical trials, clinical researchers tracking emerging therapies, and clinicians who follow experimental drug development.
What To Know
EOM Pharmaceutical says it completed preclinical IND-enabling studies for EOM613 and plans a small Phase II exploratory trial in Crohn’s disease to start in Q1 2026, enrolling about 15–20 patients at sites in New Jersey.
The company also mentions prior Phase I/IIa data in hospitalized COVID-19 patients and separate development plans for EOM613 in cancer cachexia and for other assets (EOM147) in ocular diseases. This appears to be an industry news brief summarizing the company’s development plans rather than a peer-reviewed study report.
It does not include clinical results or details on dosing, endpoints, or mechanism of action for Crohn’s disease. If you want more detail, look for the company’s original press release or clinicaltrials.gov listings for the planned Phase II trial for enrollment criteria, endpoints, and timing.
This is an early-stage company announcement and not a clinical result. Phase II here is exploratory with a small planned sample (15–20 patients); such trials are intended to assess signals of activity and safety, not to establish efficacy.
The brief was generated from company content and a third-party AI summary—refer to the original company materials or trial registry for authoritative details.
